Form 4: Amneal Pharmaceuticals Director Sells Over 56,000 Shares Under Pre-Arranged Plan

Amneal Pharmaceuticals Director Gautam Patel sold 56,426 shares of Class A Common Stock on June 10, 2025, for a weighted average price of $8.02 per share.

Summary

• Gautam Patel, a Director and 10% Owner of Amneal Pharmaceuticals, Inc. (AMRX), reported a transaction.
• The transaction involved the sale of 56,426 shares of Class A Common Stock.
• The sale occurred on June 10, 2025, at a weighted average price of $8.02 per share.
• Individual sale prices ranged from $8.00 to $8.05 per share.
• Following this transaction, Mr. Patel beneficially owns 1,704,050 shares of Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The document is a factual report of an insider stock sale. While insider selling can sometimes be perceived negatively, the disclosure that it was conducted under a Rule 10b5-1 plan suggests it was pre-scheduled and not necessarily indicative of new negative information, leading to a neutral sentiment.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide broader industry context or trends for the pharmaceutical sector.

Stakeholder Impact

• Shareholders: May observe the director's sale of shares, which could be interpreted in various ways, though the 10b5-1 plan mitigates immediate concerns about lack of confidence.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Gautam Patel, Director, Insider Sale, Form 4, Stock Transaction, Equity Sale, 10b5-1 Plan